RecruitingPhase 2NCT06978725
A Phase 2 Study of the Safety and Efficacy of Brepocitinib in Adults With Cutaneous Sarcoidosis (BEACON)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis
Sponsor
Priovant Therapeutics, Inc.
Enrollment
28 participants
Start Date
Apr 9, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria4
- Adults subjects (18-74)
- Cutaneous sarcoidosis with characteristic skin biopsy histology
- A CSAMI activity score ≥ 10
- Weight > 40 kg to < 130 kg with BMI < 40 kg/m2 .
Exclusion Criteria7
- History of
- Lymphoproliferative disorder
- Active malignancy;
- History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix).
- High risk of thrombosis or cardiovascular disease
- High risk of herpes zoster
- Active or recent infection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGOral Brepocitinib
Drug: Oral Brepocitinib
DRUGOral Placebo
Drug: Oral Placebo
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06978725